Investigating how CSDE1 regulates LDL receptor levels in the liver
CSDE1 as a Post Transcriptional Regulator of the LDLR
['FUNDING_R01'] · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · NIH-10874636
This study is looking at a protein called CSDE1 to see how it helps control the levels of LDL cholesterol in the body, which is important for heart health, and it could lead to new treatments to lower cholesterol.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (nih funded) |
| Locations | 1 site (SAN FRANCISCO, UNITED STATES) |
| Trial ID | NIH-10874636 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of CSDE1, a protein that affects the stability of LDL receptor (LDLR) mRNA, which is crucial for managing cholesterol levels in the body. By using advanced CRISPR technology, the researchers aim to uncover how CSDE1 influences LDLR and its potential as a target for new therapies to lower LDL cholesterol. The study will involve laboratory experiments to determine the mechanisms by which CSDE1 operates and its interactions with other proteins that may affect LDLR stability.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk for cardiovascular diseases due to high LDL cholesterol levels.
Not a fit: Patients with normal LDL cholesterol levels or those not at risk for cardiovascular diseases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments for lowering LDL cholesterol, thereby reducing the risk of atherosclerotic cardiovascular disease.
How similar studies have performed: Previous research has shown promising results using CRISPR technology to manipulate gene expression, indicating potential for success in this novel approach.
Where this research is happening
SAN FRANCISCO, UNITED STATES
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO — SAN FRANCISCO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CHORBA, JOHN S — UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- Study coordinator: CHORBA, JOHN S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Atherosclerotic Cardiovascular Disease